Abeona Therapeutics Inc. Common Stock (ABEO) is a publicly traded Healthcare sector company. As of May 21, 2026, ABEO trades at $5.34 with a market cap of $306.06M and a P/E ratio of -3.42. ABEO moved +4.10% today. Year to date, ABEO is +1.92%; over the trailing twelve months it is -17.13%. Its 52-week range spans $3.93 to $7.54. Analyst consensus is strong buy with an average price target of $20.67. Rallies surfaces ABEO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Abeona Therapeutics Reports Strong Q1 2026 Revenue Growth and Pipeline Update: Abeona Therapeutics posted strong Q1 2026 revenue growth and provided an update on its rare disease gene therapy clinical pipeline during its earnings call. Management discussed ongoing trials, commercial rollouts and affirmed full-year development targets.
| Metric | Value |
|---|---|
| Price | $5.34 |
| Market Cap | $306.06M |
| P/E Ratio | -3.42 |
| EPS | $-1.55 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.54 |
| 52-Week Low | $3.93 |
| Volume | 6 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-63.73M |
| Gross Margin | 0.00% |
6 analysts cover ABEO: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.67.